Herbert Lyerly
Corporate Officer/Principal bei Duke University
Vermögen: - $ am 31.03.2024
Profil
Herbert Kim Lyerly is the founder of Replicate Bioscience, Inc. He is currently a Professor at Duke University.
Previously, he served as an Independent Director at OncoSec Medical, Inc. from 2020 to 2023.
He also held the position of Director of AIDS Research at the National Institutes of Health and Director at Duke Comprehensive Cancer Center.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
21.03.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Herbert Lyerly
Unternehmen | Position | Beginn |
---|---|---|
Duke University
Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Herbert Lyerly
Unternehmen | Position | Ende |
---|---|---|
ONCOSEC MEDICAL INCORPORATED | Direktor/Vorstandsmitglied | 14.06.2023 |
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | Gründer | - |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Duke Comprehensive Cancer Center
Duke Comprehensive Cancer Center Duke Comprehensive Cancer Center develops outpatient bone-marrow transplantation program. The company is headquartered in Durham, NC. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ONCOSEC MEDICAL INCORPORATED | Health Services |
Private Unternehmen | 3 |
---|---|
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Duke Comprehensive Cancer Center
Duke Comprehensive Cancer Center Duke Comprehensive Cancer Center develops outpatient bone-marrow transplantation program. The company is headquartered in Durham, NC. | |
Replicate Bioscience, Inc.
Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | Commercial Services |